A new clinical study, led by scientists from MD Anderson Cancer Center and published in
Cancer Cell (journal impact factor = 50.3), shows that tumor and cfDNA methylation can be used to identify SCLC subtypes and might guide precision SCLC therapy. Apostle MiniMax cfDNA kit is one of the critical commercial assays listed in this article. Congratulations to this clinical research team. To date, the Apostle MiniMax technology has been used in 2 articles published in
Nature Communications, 2 in
Nature Medicine, 1 in
Science Translational Medicine, 1 in
PNAS, and over 60 scientific articles by over 60 international research and clinical teams in different journals.
.jpg-out-550x688h.jpg "96-Well ELISA Plates (50pcs)")
.jpg-out-550x688h.jpg "96-Well ELISA Plates (50pcs)")
.jpg-out-550x688h.jpg "96-Well ELISA Plates (50pcs)")
.jpg-out-550x688h.jpg "96-Well ELISA Plates (50pcs)")
.jpg-out-80x100h.jpg "96-Well ELISA Plates (50pcs)")
.jpg-out-80x100h.jpg "96-Well ELISA Plates (50pcs)")
.jpg-out-80x100h.jpg "96-Well ELISA Plates (50pcs)")
.jpg-out-80x100h.jpg "96-Well ELISA Plates (50pcs)")
